Saxenda: Underlying Mechanisms and Clinical Outcomes

NCT02944500 on ClinicalTrials.gov · last registry update 2026-05-01

A small phase 4 — 28 participants, against a typical 75. Due to report June 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: BOLD response to food cues. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since November 2016 — 9 years so far. liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: ACTIVE_NOT_RECRUITING
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Beth Israel Deaconess Medical Center
Sponsor type: Other
Enrollment: 28
Started: 2016-11
Primary completion: 2027-06 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

BOLD response to food cues

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.